Key Trends to Follow to Lead The Global Antihypertensive Drugs Market

The global antihypertensive drugs market consists of the drugs that are used to treat hypertension. Diuretics, beta-adrenergic blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are the major antihypertensive drug classes used to treat this indication.
As per the latest market research report published by Technavio, the global antihypertensive drugs market size will grow by USD 3.96 billion during 2019–2023 at a CAGR of over 2%. The increasing funds for research on hypertension and the development of modified-release formulations are some of the factors expected to drive market growth. This market report provides a detailed analysis of the market by type (systemic hypertension and pulmonary hypertension) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market top vendors in the antihypertensive drugs market including AstraZeneca, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, and Pfizer Inc.
Download the free sample report @ http://bit.ly/2mcCftn
Modified-release formulations are designed to delay the release of drug in the body after its administration. Some of the modified-release formulations consist of sustained-release and controlled-release formulations. Sustained-release formulations maintain drug release over a sustained period but not at a constant rate, whereas controlled release formulations maintain drug release over a sustained period at a nearly constant rate.
In the treatment of hypertension, continuous 24-hour control of blood pressure can be achieved with the modified-release formulations. Hence, pharmaceutical companies are developing these formulations for the treatment of hypertension.
Lung Biotechnology PBC is conducting Phase III clinical trials on BPS-314d-MR, a modified-release tablet, for the treatment of hypertension. Similarly, ALLERGAN is conducting Phase III study for evaluating intraocular pressure-lowering effect and safety of Bimatoprost SR, a sustained-release formulation, in patients with open-angle glaucoma or ocular hypertension.
Hence, the development of modified release formulations is expected to one of the key trends driving the growth of the antihypertensive drugs market at a CAGR of 2.27% during the forecast period. To know more about this market click below to get the complete reports to get the in-depth analysis of this market.
Get the Complete Report @ http://bit.ly/2mkwutw
Modified-release formulations comprise of sustained-release and controlled-release formulations. Pharmaceutical companies are actively focusing on the development of these formulations to treat hypertension as they help in achieving a continuous 24-hour control of blood pressure. Additionally, companies are also conducting studies to evaluate the safety of these formulations to treat patients with open-angle glaucoma or ocular hypertension.

Comments

Popular posts from this blog

Flexible Packaging Market – Top Insights On Forecast and Analysis 2020-2024

Liquid Silicone Rubber Market – Latest Insights on Forecast and Analysis 2020-2024

Scented Candles Market – Top Insights on The Latest Trends